-+ 0.00%
-+ 0.00%
-+ 0.00%

TOLERANCE BIO LICENSES CLINICAL-STAGE LONG-ACTING INTERLEUKIN-7 THERAPY EFINEPTAKIN ALFA FROM NEOIMMUNETECH TO ADVANCE PROGRAMS TARGETING THYMIC FUNCTION AND IMMUNE RESILIENCE

Reuters·08/19/2026 12:00:01

Please log in to view news